| Autor: |
Pedro Nazareth Aguiar Jr., Pui San Tan, Sarah Simko, Carmelia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro del Giglio, Gilberto de Lima Lopes Jr |
| Jazyk: |
English<br />Portuguese |
| Předmět: |
|
| Zdroj: |
Einstein (São Paulo), Vol 17, Iss 2 |
| Druh dokumentu: |
article |
| ISSN: |
2317-6385 |
| DOI: |
10.31744/einstein_journal/2019gs4414 |
| Popis: |
ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted Life Years. Abiraterone led to a Quality-Adjusted Life Years gain of 0.506 compared to docetaxel. The incremental costs per Quality-Adjusted Life Years were R$ 133.649,22 for docetaxel, R$ 330.828,70 for abiraterone and R$ 571.379,42 for abiraterone compared to docetaxel, respectively. Conclusion The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy. However, discounts on abiraterone cost might improve cost-effectiveness. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
